PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of heartHeartVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Heart. 1996 February; 75(2): 141–144.
PMCID: PMC484249

Time course of platelet alpha granule release in acute myocardial infarction treated with streptokinase.

Abstract

OBJECTIVE: To determine the time course of platelet alpha granule release in patients with acute myocardial infarction treated with streptokinase. DESIGN: A prospective study. SETTING: Coronary care unit. PATIENTS: Nine with myocardial infarction treated with both streptokinase and aspirin, and nine with acute chest pain but without myocardial infarction, who were treated with aspirin only. METHODS: All patients received 250 mg aspirin on admission and 150 mg once daily thereafter. All patients who fulfilled the indications for streptokinase received 1.5 megaunits, in a single infusion. After the initial medication, serial measurements of plasma beta thromboglobulin and plasma platelet factor 4 were performed at fixed intervals after the onset of chest pain. The primary endpoint sought was the peak value of beta thromboglobulin and platelet factor 4 in each individual. RESULTS: The median peak plasma beta thromboglobulin in the infarction group was substantially higher than in those without infarction, at 37 (range 12 to 210) v 15 (9 to 36) mg/litre, P < 0.01. The corresponding values for plasma platelet factor 4 were 4.6 (2.4 to 60.0) v 2.2 (< 2 to 8.5) mg/litre, P < 0.01. Increased values were seen only within the first 12 h after onset of chest pain, and after 12 h there was no difference between the patients with myocardial infarction and those without. Aspirin treatment did not abolish alpha granule release. CONCLUSIONS: In patients with acute myocardial infarction treated with streptokinase the content of the alpha granules is released within the first 12 h after the onset of chest pain. Aspirin apparently does not abolish this release.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (622K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Sylvén C, Karlberg KE, Chen J, Hagerman I, Egberg N, Bergström K. Enhanced platelet function in acute myocardial infarction is attenuated by streptokinase treatment. J Intern Med. 1992 Jun;231(6):595–600. [PubMed]
  • Udvardy M, Harsfalvi J, Boda Z, Rak K. Beta thromboglobulin and increased platelet activation after streptokinase treatment of acute myocardial infarction. Am J Cardiol. 1992 Sep 15;70(7):837–838. [PubMed]
  • Ffrench P, McGregor JL, Berruyer M, Belleville J, Touboul P, Dawes J, Dechavanne M. Comparative evaluation of plasma thrombospondin beta-thromboglobulin and platelet factor 4 in acute myocardial infarction. Thromb Res. 1985 Sep 1;39(5):619–624. [PubMed]
  • Gallino A, Haeberli A, Hess T, Mombelli G, Straub PW. Fibrin formation and platelet aggregation in patients with acute myocardial infarction: effects of intravenous and subcutaneous low-dose heparin. Am Heart J. 1986 Aug;112(2):285–290. [PubMed]
  • Seitz R, Leising H, Liebermann A, Rohner I, Gerdes H, Egbring R. Possible interaction of platelets and adrenaline in the early phase of myocardial infarction. Res Exp Med (Berl) 1987;187(5):385–393. [PubMed]
  • Jaffe AS, Lee RG, Perez JE, Geltman EM, Wilner GD, Sobel BE. Lack of elevation of platelet factor IV in plasma from patients with myocardial infarction. J Am Coll Cardiol. 1984 Oct;4(4):653–659. [PubMed]
  • Jang IK, Vanhaecke J, De Geest H, Verstraete M, Collen D, Van de Werf F. Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate and regional wall motion after 3 months. J Am Coll Cardiol. 1986 Dec;8(6):1455–1460. [PubMed]
  • Ganz W, Geft I, Shah PK, Lew AS, Rodriguez L, Weiss T, Maddahi J, Berman DS, Charuzi Y, Swan HJ. Intravenous streptokinase in evolving acute myocardial infarction. Am J Cardiol. 1984 May 1;53(9):1209–1216. [PubMed]
  • Harrison DG, Ferguson DW, Collins SM, Skorton DJ, Ericksen EE, Kioschos JM, Marcus ML, White CW. Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions. Circulation. 1984 May;69(5):991–999. [PubMed]
  • Kaplan KL, Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood. 1981 Feb;57(2):199–202. [PubMed]
  • Kaplan KL, Owen J. Plasma levels of platelet secretory proteins. Crit Rev Oncol Hematol. 1986;5(3):235–255. [PubMed]
  • Bertolino G, Noris P, Previtali M, Gamba G, Ferrario M, Montani N, Balduini CL. Platelet function after in vivo and in vitro treatment with thrombolytic agents. Am J Cardiol. 1992 Feb 15;69(5):457–461. [PubMed]
  • Carrieri P, Orefice G, Indaco A. No effect of acetylsalicylic acid on B-thromboglobulin and platelet factor 4 plasma levels in patients with transient ischaemic attacks. Stroke. 1986 Nov-Dec;17(6):1153–1155. [PubMed]

Articles from Heart are provided here courtesy of BMJ Group